| Product Unit Size | Cost | Quantity | Stock |
|---|
BLU-667 is an inhibitor of the rearranged during transfection (RET) kinase. RET is an oncogenic driver activated in multiple cancers. BLU-667 is an early selective small molecule designed to target RET, in contrast with current treatment methods that have been limited to multikinase inhibitors. BLU-667 potently inhibits growth of RET-driven non-small cell lung cancer and thyroid cancer xenografts in vtiro.
| Cas No. | 2097132-94-8 |
|---|---|
| Purity | ≥98% |
| Formula | C27H32FN9O2 |
| Formula Wt. | 533.61 |
| IUPAC Name | trans-N-{(1S)-1-[6-(4-Fluoro-1H-pyrazol-1-yl)-3-pyridinyl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl}cyclohexanecarboxamide |
| Synonym | BLU 667, BLU667, Pralsetinib |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Subbiah V., Gainor J., et al. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 8(7):836-49 (2018). PMID: 29657135.